The second Current Oncology Scholar’s Conference

Y. Cai MD PhD

Following up on its first workshop—the Current Oncology Scholar’s Forum and Workshop—on 12 May 2012 in China, Current Oncology initiated a 2nd conference in 2015, to communicate with Chinese and other Asian physicians and researchers, with the aim of exploring their current needs and interests and receiving updates on their new achievements in oncology diagnosis, treatment, prevention, recovery, and other areas of interest that intersect with oncology research.

The 2nd Current Oncology Scholars Conference was held 6–8 November 2015, in Guangzhou, China. It provided a forum for the presentation and discussion of oncology research, clinical practice, applications, and experiences from China and Asia. The conference drew more than 100 attendees, and about 50 papers were contributed to the conference. The 6 manuscripts that passed the peer review process were accepted for publication in the February 2016 issue of Current Oncology. Major topics discussed during the conference included tumour formation, molecular mechanisms, pathway analysis, pathobiology, drug resistance, clinical research, immunology, and cancer prevention.

Those topics took mainly a bench-science view, providing evidence for theoretical findings and proposing new methodologies for oncology analysis. Theoretical research is always helpful, but an equal appreciation for clinical work—which benefits doctors, research scientists, and patients overall—is also encouraged. Clinical studies in China are notably fewer in number than theoretical work, and they are far less often published in high-impact medical journals. I would like to take this opportunity to encourage all oncology researchers to put more effort into clinical areas. Based on the potential for clinical observation of larger populations in China, Chinese authors and readers have an especially great opportunity to document, share, and apply clinical findings in the current or future practice of cancer medicine worldwide.

We extend our thanks to all the oncology scientists, physicians, and research scholars in China and throughout Asia for their interest and attention. At the same time, we thank Guangzhou’s Jian Yuan Medical Technology for technological contributions to the running of the conference and for administrative support. Finally, I thank all the authors who submitted papers to the conference, and all who devoted their time and attention during the review and editing process.

Going forward, we will continue to have Current Oncology conferences in China and Asia. Your interest, attention, and support would be appreciated. We look forward to receiving your submissions, and welcome your feedback to Current Oncology.

CONFLICT OF INTEREST DISCLOSURES
I have read and understood Current Oncology’s policy on disclosing conflicts of interest, and I declare that I have none.